The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
Buti S, Tommasi C, Scartabellati G, De Giorgi U, Brighi N, Rebuzzi SE, Puglisi S, Caffo O, Kinspergher S, Mennitto A, Cattrini C, Santoni M, Verzoni E, Rametta A, Stellato M, Malgeri A, Roviello G, de Filippo M, Cortellini A, Bersanelli M.
Buti S, et al. Among authors: cattrini c.
Anticancer Drugs. 2023 Jan 1;34(1):178-186. doi: 10.1097/CAD.0000000000001356. Epub 2022 Oct 22.
Anticancer Drugs. 2023.
PMID: 36539370
Free PMC article.